Phenotypes associated with this allele
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(CMV-cre)1Cgn mutation
(6 available)
Tg(Kit*D814V)3Roer mutation
(0 available)
|
|
|
mortality/aging
|
|
• only about 25% of mice survive to adulthood
• surviving mice show signs of spontaneous regression of the hyperproliferative dysregulation of erythropoiesis
|
|
|
• rapid lethality in about 75% of neonatal mice
|
hematopoietic system
|
|
• mice appear to die of hyperproliferative dysregulation of erythropoiesis
|
|
|
• dramatic dysregulation of hematopoiesis characterized by excessive numbers of nucleated cells in the peripheral blood
• increase in nucleated cells is primarily the result of a population of small blastic cells with sparse cytoplasm
|
|
|
• survivors develop mastocytosis similar to that in mice carrying Tg(Kit*D814V)3Roer and Tg(Mx1-cre)1Cgn
|
|
|
• increase in the number of nuclear shadows in blood smears indicates the presence of cells with increased mechanical fragility
|
liver/biliary system
|
|
• most of the liver parenchyma is replaced with Ter119+ cells
|
immune system
|
|
• survivors develop mastocytosis similar to that in mice carrying Tg(Kit*D814V)3Roer and Tg(Mx1-cre)1Cgn
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
No mouse lines available in IMSR.
See publication links below for author information.
|
|
|
hematopoietic system
|
|
• accumulation of mast cells in the skin and in some cases also in the spleen
• disease symptoms occur later and disease progression is slower compared to mice carrying Tg(Kit*D814V)3Roer and Tg(Mx1-cre)1Cgn
• develop mastocytosis similar to that in mice carrying Tg(Kit*D814V)3Roer and Tg(Mx1-cre)1Cgn
|
neoplasm
|
|
• mast cell tumors are seen in some mice
|
integument
|
|
• mast cell tumors are seen in some mice
|
immune system
|
|
• accumulation of mast cells in the skin and in some cases also in the spleen
• disease symptoms occur later and disease progression is slower compared to mice carrying Tg(Kit*D814V)3Roer and Tg(Mx1-cre)1Cgn
• develop mastocytosis similar to that in mice carrying Tg(Kit*D814V)3Roer and Tg(Mx1-cre)1Cgn
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Commd10Tg(Vav1-icre)A2Kio mutation
(3 available);
any
Commd10 mutation
(24 available)
Tg(Kit*D814V)3Roer mutation
(0 available)
|
|
|
mortality/aging
|
|
• similar to the phenotype in mice carrying Tg(CMV-cre)1Cgn and Tg(Kit*D814V)3Roer
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Kit*D814V)3Roer mutation
(0 available)
Tg(Mx1-cre)1Cgn mutation
(7 available)
|
|
|
mortality/aging
|
|
• 1 pIpC treated mouse was euthanized due to severe disease at 12 weeks of age
|
digestive/alimentary system
|
|
• in mice with intestinal inflammation
|
|
|
• in mice with intestinal inflammation
|
|
|
• diarrhea with bloody feces is seen in mice with intestinal inflammation
|
|
|
• in a few mice, regardless of pIpC treatment
|
hematopoietic system
|
|
• most of the mast cells in pIpC treated mice with mastocytosis are round with some degree of hypergranulation and only few spindle shaped cells are seen
|
|
|
• mice treated with 3 injections of pIpC every second day at 4 to 10 weeks of age develop diffuse mastocytosis by 13 - 38 weeks of age
• pIpC treated mice display a variable increase in cutaneous mast cell numbers
• in some pIpC treated mice accumulations of mast cells are seen in the lymph nodes
• mice not treated with pIpC develop phenotypes similar to those in pIpC injected mice
|
|
|
• bone marrow cells are unable to engraft in nonirradiated recipient mice
|
neoplasm
|
|
• some pIpC treated mice develop large numbers of dermal mast cell tumors of variable size
• in a few mice these tumors are macroscopically visible
• mice not treated with pIpC develop phenotypes similar to those in pIpC injected mice
|
|
|
• some mice, regardless of pIpC treatment, develop a condition resembling B-lymphoblastic leukemia
|
growth/size/body
|
|
• in mice with intestinal inflammation
|
integument
|
|
• some pIpC treated mice develop large numbers of dermal mast cell tumors of variable size
• in a few mice these tumors are macroscopically visible
• mice not treated with pIpC develop phenotypes similar to those in pIpC injected mice
|
immune system
|
|
• in a few mice, regardless of pIpC treatment
|
|
|
• most of the mast cells in pIpC treated mice with mastocytosis are round with some degree of hypergranulation and only few spindle shaped cells are seen
|
|
|
• mice treated with 3 injections of pIpC every second day at 4 to 10 weeks of age develop diffuse mastocytosis by 13 - 38 weeks of age
• pIpC treated mice display a variable increase in cutaneous mast cell numbers
• in some pIpC treated mice accumulations of mast cells are seen in the lymph nodes
• mice not treated with pIpC develop phenotypes similar to those in pIpC injected mice
|
Analysis Tools